Lesson plan
REG1
REG1 is an anticoagulation system consisting of two drugs: pegnivacogin, a single-stranded 31-nucleotide aptamer that binds and inhibits Factor IXa, and anivamersen, a complementary sequence reversal 15-nucleotide control agent. REG1 mechanism of action It involves inhibition of Factor IXa. REG1 is being developed for use in patients undergoing percutaneous coronary intervention and the treatment of acute coronary syndrome. REG1 is associated with severe allergic reactions. In the phase 2b RADAR trial, 12 allergic-like reactions occurred shortly after administration of pegnivacogin in three patients with histories of allergy. In one clinical trial, it was found that there was no evidence that REG1 reduced ischaemic events or bleeding compared with bivalirudin.
Article summary
REG1 is an anticoagulation system consisting of two drugs: pegnivacogin, a single-stranded 31-nucleotide aptamer that binds and inhibits Factor IXa, and anivamersen, a complementary sequence reversal 15-nucleotide control agent. REG1 mechanism of action It involves inhibition of Factor IXa. REG1 is being developed for use in patients undergoing percutaneous coronary intervention and the treatment of acute coronary syndrome. REG1 is associated with severe allergic reactions. In the phase 2b RADAR trial, 12 allergic-like reactions occurred shortly after administration of pegnivacogin in three patients with histories of allergy. In one clinical trial, it was found that there was no evidence that REG1 reduced ischaemic events or bleeding compared with bivalirudin.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.